Meanwhile, the changes of CSF VLP-1 in AD patients relative to healthy controls and MCI patients were less pronounced than that of core CSF biomarkers, including Ab42, t-tau and p-tau. The gene discussed is MAPT; the disease is Alzheimer disease.